SLC5A2 and type 2 diabetes mellitus: Further research found that combining metformin with sodium glucose cotransporter-2 (SGLT2) inhibitor can enhance therapeutic outcomes by lowering fasting blood glucose, increasing the urinary glucose-to-creatinine ratio, and significantly reducing body weight and blood pressure in clinical populations with T2D (16).